Hola,
Are you new here?

Fucoderm

financed

An effective side effect free topical emollient treatment for atopic dermatitis...

An effective side effect free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract Atopic dermatitis (AD), a chronic inflammatory skin disease characterised by itchy skin lesions and rashes, affects 1 child in 5-10, and 3% of adults. Without effective treatment it can have a severe negative impact on quality of... see more

31/03/2017

GlycoMar

71K€

Project Budget: 71K€

Project leader

GLYCOMAR LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2017-03-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada does 9 years

0% 70% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

GlycoMar

50.00K€ | Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 3 months Date Start: 2016-12-06
End date: 2017-03-31

Project leader

GLYCOMAR LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 71K€

participation deadline Sin fecha límite de participación.

Project description Atopic dermatitis (AD), a chronic inflammatory skin disease characterised by itchy skin lesions and rashes, affects 1 child in 5-10, and 3% of adults. Without effective treatment it can have a severe negative impact on quality of life. Treatment has historically been dominated by topical steroid creams, although consumers – reticent to using steroids over long periods, and for convenience (some steroid treatments are prescription only) – are increasingly opting for non-pharma products with natural attributes. These natural products, however, tend to have high toxicity and therefore to create unpleasant side effects. Glycomar’s eczema treatment, Fucoderm, directly addresses these shortcomings and responds to consumer preferences. Using an active pharmaceutical ingredient extracted from brown seaweed – a Fucoidan – Glycomar has created a novel topical formulation for maintenance treatment. The product is the first commercial application of Glycomar’s extensive glycobiology expertise – the team has over 100 years’ collective experience in marine biotechnology and drug discovery/development – and it will be targeted towards mild- to moderate AD sufferers. Together these cases comprise 80-90% of the €4b market, which is growing at 3,8% – maximising potential impact. The company, which has been working for 10 years in pursuit of novel immunomodulatory saccharides, has a track record of attracting non-dilutive grant funding, and of creating cash generative, value enhancing partnerships. Successful commercialisation of Fucoderm would enable Glycomar to meet its target of reaching profitability by 2019, in turn facilitating the launch of other consumer healthcare, nutraceutical and cosmetic products in the development pipeline.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers